リドカイン（注射液中）　Lidocaine (in parenteral solution)

日本薬局方におけるカラム選定条件は，「リドカイン，内標準物質の順に溶出し，その分離度が 6 **以上あるものを用いる」と定められています．**CAPCELL PAK C_{18} MGII **では，分離度が** 7.8 **でした．**

The Japanese Pharmacopoeia requires a column to elute compounds in the order of lidocain and its internal standard, with a resolution value of 6 or greater between the two compounds. CAPCELL PAK C_{18} MGII showed a resolution of 7.8.





1. リドカイン (2 mg/mL)
   Lidocaine (M.W. 234.3)
2. ベンゾフェノン (I.S.) (50 μg/mL)
   Benzophenone (I.S.) (M.W. 182.2)

【HPLC Conditions】

Column	:	CAPCELL PAK C_{18} MGII S5 ; 4.6 mm i.d. x 150 mm
Mobile phase	:	{20 mmol/L KH_2PO_4 (adjusted at pH 3.0 with phosphoric acid) / CH_3CN = 55 / 45} / Sodium dodecyl sulfate = 1000 mL / 2.88 g
Flow rate	:	1.8 mL/min
Temperature	:	25 ˚C
Detection	:	UV 254 nm
Inj. vol.	:	5 μL
Sample dissolved in	:	0.5 mL of 1 mol/mL HCl was added to 100 mg of lidocaine. A few milliliters of 1 mmol/L HCl was further added so that the compound be completely dissolved. 10 mL of the internal standard solution (benzophenone in methanol, 250 μg/mL) was added to the solution. The solution was diluted to 50 mL in a volumetric flask with 1 mmol/L HCl.

※ 1 μg/mL = 1 ppm